Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Adr 529
2. Adr-529
3. Adr529
4. Cardioxan
5. Cardioxane
6. Dexrazoxane
7. Hydrochloride, Dexrazoxane
8. Icrf 187
9. Icrf-187
10. Icrf187
11. Nsc 169780
12. Nsc-169780
13. Nsc169780
14. Razoxane, (s)-isomer
15. Razoxane, (s)-isomer, Hydrochloride
16. Zinecard
1. 149003-01-0
2. Dexrazoxane Hcl
3. Totect
4. Cardioxane
5. Zinecard
6. Cardioxan
7. Savene
8. Adr-529 Hydrochloride
9. Icrf-187 Hydrochloride
10. Icrf-187
11. 1263283-43-7
12. (+)-razoxane Hydrochloride
13. Razoxane Hydrochloride, (s)-
14. Dexrazoxane (hydrochloride)
15. 4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione Hydrochloride
16. Dexrazoxane Hydrochloride [vandf]
17. Dexrazoxane Hydrochloride [who-dd]
18. 2,6-piperazinedione, 4,4'-((1s)-1-methyl-1,2-ethanediyl)bis-, Hydrochloride (1:1)
19. Razoxane (+)-form Hydrochloride [mi]
20. Dexrazoxane Hydrochloride [orange Book]
21. 5346058q7s
22. (s)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione) Hydrochloride
23. Dexrazoxane Hcl (icrf-187, Adr-529)
24. 2,6-piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, Hydrochloride, (s)-
25. Chebi:50224
26. Icrf 187 Hydrochloride
27. Topotect
28. Unii-5346058q7s
29. Zinecard (tn)
30. (s)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione Hydrochloride
31. Savene (tn)
32. Totect (tn)
33. Dexrazoxanehydrochloride
34. Cardioxane Hydrochloride
35. Schembl18188
36. Chembl1200778
37. Dtxsid60164152
38. 4-[(2s)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione;hydrochloride
39. Kdx-0811
40. S1222
41. Akos015900046
42. Ac-9014
43. Ccg-267515
44. As-16976
45. Dexrazoxane Hcl (icrf-187; Adr-529)
46. Sw220147-1
47. C72836
48. D07807
49. 003d010
50. Dexrazoxane Hydrochloride (icrf-187, Adr-529)
51. Q27121988
| Molecular Weight | 304.73 g/mol |
|---|---|
| Molecular Formula | C11H17ClN4O4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | 304.0938327 g/mol |
| Monoisotopic Mass | 304.0938327 g/mol |
| Topological Polar Surface Area | 98.8 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 404 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Dexrazoxane hydrochloride |
| PubMed Health | Dexrazoxane (Injection) |
| Drug Classes | Cardioprotective Agent, Dermatological Agent |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 250mg base/vial |
| Market Status | Prescription |
| Company | Mylan Institutional; Eurohlth Intl |
| 2 of 6 | |
|---|---|
| Drug Name | Totect |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Biocodex |
| 3 of 6 | |
|---|---|
| Drug Name | Zinecard |
| PubMed Health | Dexrazoxane (Injection) |
| Drug Classes | Cardioprotective Agent, Dermatological Agent |
| Drug Label | ZINECARD (dexrazoxane for injection), a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration.Chemically, dexrazoxane is (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2 |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 250mg base/vial |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 4 of 6 | |
|---|---|
| Drug Name | Dexrazoxane hydrochloride |
| PubMed Health | Dexrazoxane (Injection) |
| Drug Classes | Cardioprotective Agent, Dermatological Agent |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 250mg base/vial |
| Market Status | Prescription |
| Company | Mylan Institutional; Eurohlth Intl |
| 5 of 6 | |
|---|---|
| Drug Name | Totect |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial |
| Market Status | Prescription |
| Company | Biocodex |
| 6 of 6 | |
|---|---|
| Drug Name | Zinecard |
| PubMed Health | Dexrazoxane (Injection) |
| Drug Classes | Cardioprotective Agent, Dermatological Agent |
| Drug Label | ZINECARD (dexrazoxane for injection), a cardioprotective agent for use in conjunction with doxorubicin, is a sterile, pyrogen-free lyophilizate intended for intravenous administration.Chemically, dexrazoxane is (S)-4,4'-(1-methyl-1,2-ethanediyl)bis-2 |
| Active Ingredient | Dexrazoxane hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 500mg base/vial; eq 250mg base/vial |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
Savene is indicated for the treatment of anthracycline extravasation.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Cardiotonic Agents
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
V03AF02
V03AF02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 250MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 250MG BASE/VIAL
USFDA APPLICATION NUMBER - 20212
DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE/VIAL
USFDA APPLICATION NUMBER - 20212
DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE...DOSAGE - INJECTABLE;INJECTION - EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 22025
Related Excipient Companies
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
